PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable with senior figures from the Algerian Ministry of Health, AstraZeneca, Novo Nordisk, Clinica, the National Association of Pharmacy Producers, the Chief Economist of the The European Federation of Pharmaceutical…

Algeria PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable. Algeria’s youthful pharmaceutical landscape includes an array of state-controlled entities of an industrial or commercial nature alongside more conventional regulatory apparatus.  THE NATIONAL AGENCY FOR…

PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. The sector looks healthy on the surface: it has a market valuation of USD 3 billion, and double-digit sector growth. But now, Algeria must find a way to access more innovative treatments, accommodate existing local players in…

Two companies from two different countries chose Mexico as their entry market to Latin America. The heads of these companies spoke to PharmaBoardroom about their market entry strategies. Edmée Stenken, senior area director Latin America, Leo Pharma Many things have changed at Leo Pharma in the last 15 years: we…

Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…

Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

Generics The Moroccan pharma sector is increasingly looking not just to Europe, but also to Africa. Moroccan investment in distribution to African countries is increasing. But key opinion leaders say that challenges remain. For example, Morocco would benefit from a direct export platform. “In the past Morocco always looked towards the north…

healthcare In the past, the Moroccan pharmaceutical sector primarily served local needs. Now it is ramping up its research and development capabilities, looking outwards to global markets, developing partnerships with other African countries, and beginning to think about social programs such as public access to healthcare. “[Morocco’s] success grew from a…

In its July issue, Pharmaceutical Executive announced the results of its Emerging Pharma Leaders list for 2015. PharmaBoardroom is pleased to reveal that two of its previous interviewees, from its latest reports in Mexico and India, were included in this list of emerging leaders. Selected independently by the magazine’s editorial…

market access Many of the multinational companies with a long-standing presence in Latin America used to have factories in Peru – since the 1990s all of these companies have closed their facilities in the country as part of a consolidation process to other larger countries in the region like Mexico, Brazil or…

access In modern terms, Peru’s healthcare system was largely underdeveloped for many years; but the economic fortune that Peru has experienced in more recent years has allowed for a significant overhaul and reform of the system. However, the road to health reform is rocky. Peruvian Congressman Gustavo Rondón, secretary for the…